Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Paganin, Patrizia ^a   Fiscarelli, Ersilia Vita ^b   Tuccio, Vanessa ^b   Chiancianesi, Manuela ^c   Bacci, Giovanni ^c   Morelli, Patrizia ^d   Dolce, Daniela ^e   Dalmastri, Claudia ^a   De Alessandri, Alessandra ^d   Lucidi, Vincenzina ^b   Taccetti, Giovanni ^e   Mengoni, Alessio ^c   Bevivino, Annamaria ^a  

^a ENEA C R CASACCIA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIUM CULTURE; BURKHOLDERIA; CANDIDA ALBICANS; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MICROBIAL COMMUNITY; MICROBIAL IDENTIFICATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ROTHIA MUCILAGINOSA; SHEWANELLA; SPECIES DIVERSITY; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; ADOLESCENT; DISEASE COURSE; GENETICS; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; MICROFLORA; MOLECULAR TYPING; PATHOPHYSIOLOGY; SPUTUM; YOUNG ADULT;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; CANDIDA ALBICANS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; ROTHIA MUCILAGINOSA; SHEWANELLA; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; BURKHOLDERIA; CANDIDA ALBICANS; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MICROBIOTA; MOLECULAR TYPING; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PSEUDOMONAS AERUGINOSA; SHEWANELLA; SPUTUM; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84929483843     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124348     Document Type: Article

References (59)

1. Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL, et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax. 2012; 67: 860-866. doi: 10.1136/thoraxjnl-2011-200953 PMID: 22555277
2. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, et al. on behalf of the ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J. 2014; 43: 125-133. doi: 10.1183/09031936.00166412 PMID: 23598952
3. Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. 2004; 126: 412-419. doi: 10.1378/chest.126.2.412 PMID: 15302726
4. Sanders DB, Bittner RCL, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010; 182: 627-632. doi: 10.1164/rccm.200909-1421OC PMID: 20463179
5. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007; 151: 134-139. doi: 10.1016/j.jpeds.2007.03.006 PMID: 17643762
6. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest. 1998; 113: 1230-1234. doi: 10.1378/chest.113.5.1230 PMID: 9596299
7. Stressmann FA, Rogers GB, Klem ER, Lilley AK, Donaldson SH, Daniels TW, et al. Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers. J Clin Microbiol. 2011; 49: 281-291. doi: 10.1128/JCM.01650-10 PMID: 21068277
8. Huang YJ, Lynch SV. The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications. Expert Rev Respir Med. 2011; 5: 809-821. doi: 10.1586/ers.11.76 PMID: 22082166
9. Rogers GB, Shaw D, Marsh RL, Carroll MP, Serisier DJ, Bruce KD. Respiratory microbiota: addressing clinical questions, informing clinical practice. Thorax. 2015; 70: 74-81. doi: 10.1136/thoraxjnl-2014-205826 PMID: 25035125
10. Rogers GB, Skelton S, Serisier DJ, van der Gast CJ, Bruce KD. Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2010; 48: 78-86. doi: 10.1128/JCM.01324-09 PMID: 19906901
11. Lynch S V, Bruce KD. The cystic fibrosis airway microbiome. Cold Spring Harb Perspect Med. 2013; 3: a009738. doi: 10.1101/cshperspect.a009738 PMID: 23457293
12. Zhao J, Murray S, Lipuma JJ. Modeling the impact of antibiotic exposure on human microbiota. Sci Rep. 2014; 4: 4345. doi: 10.1038/srep04345 PMID: 24614401
13. Mahenthiralingam E. Emerging cystic fibrosis pathogens and the microbiome. Paediatr Respir Rev. 2014; 15: 13-15. doi: 10.1016/j.prrv.2014.04.006 PMID: 24832700
14. Carmody LA, Zhao J, Schloss PD, Petrosino JF, Murray S, Young VB, et al. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc. 2013; 10: 179-187. doi: 10.1513/AnnalsATS.201211-107OC PMID: 23802813
15. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev. 2011; 24: 29-70. doi: 10.1128/CMR.00036-10 PMID: 21233507
16. Sibley CD, Parkins MD, Rabin HR, Surette MG. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr Opin Investig Drugs. 2009; 10: 787-794. PMID: 19649923
17. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153: S4-S14. doi: 10.1016/j.jpeds.2008.05.005 PMID: 18639722
18. Kerem E, Conway S, Elborn S, Heijerman H for the Consensus Committee. Standards of care for patients with cystic fibrosis: A European consensus. J Cyst Fibros. 2005; 4: 7-26. PMID: 15996905
19. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009; 180: 802-808. doi: 10.1164/rccm.200812-1845PP PMID: 19729669
20. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. for the Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994; 331: 637-642. doi: 10.1056/NEJM199409083311003 PMID: 7503821
21. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. for the Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999; 340: 23-30. doi: 10.1056/NEJM199901073400104 PMID: 9878641
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005; 26: 319-338. doi: 10.1183/09031936.05.00034805 PMID: 16055882
23. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med. 2008; 177: 995-1001. doi: 10.1164/rccm.200708-1151oc PMID: 18263800
24. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998; 27: 158-163. PMID: 9675470
25. Seng P, Abat C, Rolain JM, Colson P, Lagier JC, Gouriet F, et al. Identification of rare pathogenic bacteria in a clinical microbiology laboratory: impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2013; 51: 2182-2194. doi: 10.1128/JCM.00492-13 PMID: 23637301
26. Del Chierico F, Masotti A, Onori M, Fiscarelli E, Mancinelli L, Ricciotti G, et al. MALDI-TOF MS proteomic phenotyping of filamentous and other fungi from clinical origin. J Proteomics. 2012; 75: 3314-3330. doi: 10.1016/j.jprot.2012.03.048 PMID: 22504628
27. Bittar F, Rolain JM. Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect. 2010; 16: 809-820. doi: 10.1111/j.1469-0691.2010.03236.x PMID: 20880410
28. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2004; 42: 5176-5183. doi: 10.1128/JCM.42.11.5176-5183.2004 PMID: 15528712
29. McCafferty J, Reid R, Spencer M, Hamp T, Fodor A. Peak Studio: a tool for the visualization and analysis of fragment analysis files. Environ Microbiol Rep. 2012; 4: 556-561. doi: 10.1111/j.1758-2229.2012.00368.x PMID: 23760901
30. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN: 3-900051-07-0. 2014. Available: http://www.R-project.org/.
31. Shyu C, Soule T, Bent SJ, Foster JA, Forney LJ. MiCA: a web-based tool for the analysis of microbial communities based on terminal-restriction fragment length polymorphisms of 16S and 18S rRNA genes. Microb Ecol. 2007; 53: 562-570. doi: 10.1007/s00248-006-9106-0 PMID: 17406775
32. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA. 2012; 109: 5809-5814. doi: 10.1073/pnas.1120577109 PMID: 22451929
33. Vandenbranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL, Konstan MW, et al. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol. 2012; 47: 135-143. doi: 10.1002/ppul.21526 PMID: 22241571
34. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31: 416-468. doi: 10.1183/09031936.00099306 PMID: 18238951
35. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34: 91-100. doi: 10.1002/ppul.10127 PMID: 12112774
36. Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guidelines for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014; 35 (Supply 1): S1-S67. doi: 10.1086/676882
37. Foweraker J. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br Med Bull. 2009; 89: 93-110. doi: 10.1093/bmb/ldn050 PMID: 19155262
38. Maeda Y, Elborn JS, Parkins MD, Reihill J, Goldsmith CE, Coulterf WA, et al. Population structure and characterization of viridans group streptococci (VGS) including Streptococcus pneumoniae isolated from adult patients with cystic fibrosis (CF). J Cyst Fibros. 2011; 10: 133-139. doi: 10.1016/j.jcf.2010.11 PMID: 21145793
39. Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, Sarles J, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One. Public Library of Science; 2008; 3: e2908. doi: 10.1371/journal.pone.0002908 PMID: 18682840
40. Guss AM, Roeselers G, Newton ILG, Young CR, Klepac-Ceraj V, Lory S, et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J. 2011; 5: 20-29. doi: 10.1038/ismej.2010.88 PMID: 20631810
41. Lim YW, Schmieder R, Haynes M, Furlan M, Matthews TD, Whiteson K, et al. Mechanistic model of Rothia mucilaginosa adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic data. PLoS One. Public Library of Science; 2013; 8: e64285. doi: 10.1371/journal.pone.0064285
42. Chotirmall SH, O'Donoghue E, Bennett K, Gunaratnam C, O'Neill SJ, McElvaney NG. Sputum Candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis. Chest. 2010; 138: 1186-1195. doi: 10.1378/chest.09-2996 PMID: 20472859
43. Bevivino A, Bragonzi A. The evolving polymicrobial composition in the airways of patients with cystic fibrosis: implications for disease progression and clinical management. CML Cystic Fibrosis. 2013; 3: 93-104.
44. Liu WT, Marsh TL, Cheng H, Forney LJ. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. Appl Environ Microbiol. 1997; 63: 4516-4522. doi: 0099-2240/97/$04.00+0 PMID: 9361437
45. Osborn AM, Moore ER, Timmis KN. An evaluation of terminal-restriction fragment length polymorphism (T-RFLP) analysis for the study of microbial community structure and dynamics. Environ Microbiol. 2000; 2: 39-50. doi: 10.1046/j.1462-2920.2000.00081.x PMID: 11243261
46. Marsh TL, Jared RL. Culture-independent microbial community analysis with terminal restriction fragment length polymorphism. Methods Enzymol. 2005; 397: 308-329. doi: 10.1016/S0076-6879(05)97018-3 PMID: 16260299
47. Tiquia SM. Using terminal restriction fragment length polymorphism (T-RFLP) analysis to assess microbial community structure in compost systems. Methods Mol Biol. 2010; 599: 89-102. doi: 10.1007/978-1-60761-439-5-6 PMID: 19882281
48. Joo S, Lee S-R, Park S. Monitoring of phytoplankton community structure using terminal restriction fragment length polymorphism (T-RFLP). J Microbiol Methods. 2010; 81: 61-68. doi: 10.1016/j.mimet.2010.01.025 PMID: 20138925
49. Nakano Y, Takeshita T, Yasui M, Yamashita Y. Prediction of plausible bacterial composition based on terminal restriction fragment length polymorphisms using a Monte Carlo method. Microb Ecol. 2010; 60: 364-372. doi: 10.1007/s00248-010-9703-9 PMID: 20574825
50. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2003; 41: 3548-3558. doi: 10.1128/JCM.41.8.3548-3558.2003 PMID: 12904354
51. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA. 2008; 105: 15070-15075. doi: 10.1073/pnas.0804326105 PMID: 18812504
52. Camarinha-Silva A, Wos-Oxley ML, Jáuregui R, Becker K, Pieper DH. Validating T-RFLP as a sensitive and high-throughput approach to assess bacterial diversity patterns in human anterior nares. FEMS Microbiol Ecol. 2012; 79: 98-108. doi: 10.1111/j.1574-6941.2011.01197.x PMID: 22066869
53. Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, et al. Prevalence of Streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol. 2012; 194: 4709-4717. doi: 10.1128/JB.00566-12 PMID: 22753064
54. Cai L, Ye L, Tong AHY, Lok S, Zhang T. Biased diversity metrics revealed by bacterial 16S pyrotags derived from different primer sets. PLoS One. Public Library of Science; 2013; 8: e53649. doi: 10.1371/journal.pone.0053649
55. Taberlet P, Coissac E, Pompanon F, Brochmann C, Willerslev E. Towards next-generation biodiversity assessment using DNA metabarcoding. Mol Ecol. 2012; 21: 2045-2050. doi: 10.1111/j.1365-294X.2012.05470.x PMID: 22486824
56. Maughan H, Wang PW, Diaz Caballero J, Fung P, Gong Y, Donaldson SL, et al. Analysis of the cystic fibrosis lung microbiota via serial Illumina sequencing of bacterial 16S rRNA hypervariable regions. PLoS One. Public Library of Science; 2012; 7: e45791. doi: 10.1371/journal.pone.0045791 PMID: 23056217
57. Lim YW, Evangelista JS, Schmieder R, Bailey B, Haynes M, Furlan M, et al. Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. J Clin Microbiol. 2014; 52: 425-437. doi: 10.1128/JCM.02204-13 PMID: 24478471
58. Blackwood CB, Hudleston D, Zak DR, Buyer JS. Interpreting ecological diversity indices applied to terminal restriction fragment length polymorphism data: insights from simulated microbial communities. Appl Environ Microbiol. 2007; 73: 5276-5283. doi: 10.1128/AEM.00514-07 PMID: 17601815
59. Ding T, Palmer MW, Melcher U. Community terminal restriction fragment length polymorphisms reveal insights into the diversity and dynamics of leaf endophytic bacteria. BMC Microbiol. 2013; 13: 1. doi: 10.1186/1471-2180-13-1 PMID: 23286760